Search 

UB is a premier, research-intensive public university and a member of the Association of American Universities. As the largest, most comprehensive institution in the 64-campus State University of New York system, our research, creative activity and people positively impact the world. 

As a SUNY Distinguished Professor and Associate Director of the New York State Center of Excellence in Bioinformatics and Life Sciences, Dr. Morse has extensive experience in coordinating and governing multidisciplinary research efforts involving health information technology to improve patient safety. Dr. Morse also directs the Empire State Patient Safety Assurance Network, an AHRQ-designated, federally certified Patient Safety Organization and has led the UB 2020 effort to develop a model for statewide medication management programs in partnership with the NYS Department of Health Patient Safety Center. Dr. Morse has also worked with UB to establish the ESPSAN as a component of the UB 2020 planning process, a program that includes the School of Pharmacy and Pharmaceutical Sciences, Nursing, Medicine and Public Health. He also developed the UB Pharmacotherapy Information Center (PIC) and has led an effort to develop model medication management programs in Western New York and established the regional HIV Adherence-Pharmacology Program. Dr. Morse is also Co-Director of the UNYTE Translational Research Network of the University of Rochester CTSI, regional network composed of 18 academic and research institutions. In addition, Dr. Morse is the Director of the Translational Pharmacology Research Core in the New York State Center of Excellence in Bioinformatics and Life Sciences. Dr. Morse also holds appointments as a Professor in the Department of Pharmacy Practice, and Research Professor of Medicine and Pediatrics, at the University at Buffalo. Dr. Morse was previously the Associate Dean of Clinical and Translational Research in the School of Pharmacy and Pharmaceutical Sciences at the University at Buffalo.

VentriNova is a regenerative medicine company focused on reversing cardiac damage by activation of intrinsic repair pathways to generate de novo heart muscle cells. VentriNova’s first generation product is a gene therapy that delivers a critical mitotic regulator to diseased heart tissue to stimulate proliferation of cardiac muscle cells.

• No technology on the market or in clinical development, including stem cell-based technologies and other regenerative medicine applications, has the ability to grow new heart muscle cells in the diseased heart.

• VentriNova’s pioneering science and technology is centered on development of biologic and small molecule regulators of the cyclin A2 gene – the key switch mediating heart cell division.

• VentriNova’s technology demonstrated in both small and large animals the ability to control the modulation (increased gene expression) of the cyclin A2 gene, therefore stimulating endogenous growth of new myocytes (heart muscle cells).

• VentriNova’s VN-100 technology is the conductor that orchestrates existing human heart
  cells to divide and regenerate themselves – a cellular function that is silenced in early human development.

The VIE Program is a hassle-free HR package offered by the French government which allows your company to recruit highly skilled young professionals from Europe.  It is entirely flexible and comes with many financial advantages, which explains why the program is so successful. There are currently 8200 VIEs assigned in 1800 companies worldwide and the US is the #1 destination with more than 1000 VIEs currently assigned.

Visterra is a biotechnology company that uses its proprietary Hierotope™ Platform to identify unique disease targets and design and engineer effective therapeutics. The company’s technology is powered by computational tools and techniques, the core of which is Atomic Interaction Network (AIN) analysis, which uniquely identifies an area, or epitope, on the target site that is fundamental to its structure and function. This ideal epitope, or hierotope, becomes the target against which the company designs a novel therapeutic to effectively and durably combat the disease. 

The company is currently focused on therapeutics for infectious diseases, and its lead product candidate, VIS410, is a broad spectrum human monoclonal antibody for the prevention and treatment of both seasonal and pandemic influenza. The company’s second product candidate, VIS513, is a human monoclonal antibody for the treatment of dengue that has been shown to broadly neutralize all four dengue virus serotypes.

A full service investment banking and securities brokerage firm which serves the needs of both private and public companies worldwide, as well as individual and institutional investors.

We are committed to forging lasting partnerships with emerging growth companies and the investors who back them. Our simple approach is to provide customized financial solutions for virtually any need. A complete range of investment banking and brokerage services are available to our valued corporate and individual clients.

Widener University is a nationally-recognized, private university where academics, leadership, and service matter.

Founded in 1821, Widener is among the nation’s top universities for civic engagement.

We offer liberal arts and sciences and professional programs leading to associate’s, baccalaureate, master’s, and doctoral degrees.

We have a long history of turning out leaders with a formula that works. At Widener, we believe that academic excellence, career preparation, and civic engagement lead to success.

Our close-knit community includes top-notch teachers, nationally renowned researchers, and students from 22 states and 26 countries who are passionate about learning, leadership, and making a difference.

When they are not engaged in experiential learning assignments, our students and faculty members lend a hand through community service projects in our hometown of Chester and in communities around the world.

In addition, with Philadelphia only 20 minutes away, we have a living laboratory where students earn practicalexperience through internships and co-op opportunities. 

Our beautiful 110-acre main campus in Chester is a great place to live, study, and have fun, and we have satellite campuses in Exton and Harrisburg, Pennsylvania, and in Wilmington, Delaware, too.